No Data
Hong Kong stock movement | Zhenxin Biotechnology-B (02509) rose over 5% as the supplementary application for a new indication of Ustinumab injection was accepted by the NMPA.
Chun Shin Biotech Co., Ltd. - Class B (02509) rose more than 5%, as of the time of publication, it rose by 5.57%, closing at 11.38 Hong Kong dollars, with a turnover of 0.7366 million Hong Kong dollars.
Chongxin Biotech-B (02509.HK): The supplementary application of QX001S (Ustekinumab Injection) for children with plaque psoriasis has been accepted.
The announcement from Cansino Biologics-B (02509.HK) on December 2 revealed details about the QX001S framework agreement entered into with Hangzhou CMS East Pharmaceutical Co., Ltd. ("CMS East"), with the announcement published on September 12, 2024, regarding CMS East and the company's subsidiary Jiangsu Saifusheng Biotechnology Co., Ltd. ("Saifusheng") signing the "Wushinu Monoclonal Antibody Commissioned Production Agreement" Supplementary Agreement and setting the annual ceiling of the QX001S framework agreement, as well as the announcement published on November 5, 2024, concerning CMS East's receipt of national pharmaceutical products.
Express News | Qyuns Therapeutics Co Ltd - Subscription of Wealth Management Products
Retail Investors Invested in Qyuns Therapeutics Co., Ltd. (HKG:2509) Copped the Brunt of Last Week's HK$573m Market Cap Decline
Express News | Qyuns Therapeutics - QX001S (Sailexin, Ustekinumab Injection) Drug Registration Certificate Approved and Issued by Nmpa
CSPC Pharmaceutical Group Limited-B (02509.HK): China Securities Regulatory Commission accepted the company's H股全流通计划申请.
Great Wall News October 28th, Quansin Biotech-B (02509.HK) announced that the China Securities Regulatory Commission has recently accepted the company's shareholders' suggestions to implement the application for full circulation of H shares. According to the relevant application documents, the company has applied to convert 17,322,400 shares held by certain shareholders into H shares and list them on the Hong Kong Stock Exchange, accounting for approximately 7.80% of the company's total issued share capital as of the announcement date. After the full circulation of H shares, all domestic shareholders participating in the full circulation of H shares will still need to comply with the share lock-up requirements under the Hong Kong Stock Exchange listing rules and applicable laws and regulations.
No Data
No Data